Sintx Details Executive Pay for 2024, Highlighting Equity Incentives
Ticker: SINT · Form: DEF 14A · Filed: Jul 31, 2025 · CIK: 1269026
| Field | Detail |
|---|---|
| Company | Sintx Technologies, Inc. (SINT) |
| Form Type | DEF 14A |
| Filed Date | Jul 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: Executive Compensation, DEF 14A, Surgical Instruments, Medical Devices, Corporate Governance, Equity Awards, Shareholder Value
Related Tickers: SINT
TL;DR
**SINT's executive compensation structure, heavy on equity, signals a focus on long-term retention but could dilute shareholder value.**
AI Summary
Sintx Technologies, Inc. (SINT) filed a DEF 14A on July 31, 2025, outlining executive compensation for the fiscal year ending December 31, 2024. The filing details compensation for key executives, including Eric Olson and B. Sonny Bal, and other non-principal executive officers and non-named executive officers. For the period January 1, 2024, to July 31, 2024, Eric Olson's compensation included adjustments for grant date values in the Summary Compensation Table, year-end fair value of unvested awards granted in the current year, and year-over-year differences for unvested awards from prior years. Similarly, B. Sonny Bal's compensation is detailed for the period August 1, 2024, to December 31, 2024, covering the same categories. The filing also provides data for the full fiscal year 2023 for comparison, indicating a consistent structure for executive remuneration. Specific dollar amounts for revenue and net income are not provided in this DEF 14A, as it focuses on executive compensation and not financial performance metrics. The strategic outlook is implicitly tied to retaining executive talent through competitive compensation packages.
Why It Matters
This DEF 14A filing is crucial for investors as it provides transparency into Sintx Technologies' executive compensation structure, directly impacting shareholder value through potential dilution from equity awards. Understanding how executives like Eric Olson and B. Sonny Bal are incentivized can shed light on leadership's alignment with long-term company performance. For employees, it sets a benchmark for compensation practices within the company. In the competitive medical instruments sector, attracting and retaining top talent is paramount, and these compensation details offer insight into Sintx's strategy to do so, potentially influencing its ability to innovate and compete against rivals like Stryker or Zimmer Biomet.
Risk Assessment
Risk Level: medium — The risk level is medium because while the filing provides transparency on executive compensation, the heavy reliance on equity awards, as indicated by 'YearEndFairValueOfUnvestedAwardsGrantedInTheCurrentYear' and 'YearOverYearDifferenceOfYearEndFairValuesForUnvestedAwardsGrantedInPriorYears' for executives like Eric Olson and B. Sonny Bal, could lead to significant shareholder dilution if not managed effectively. This compensation structure ties executive incentives to stock performance, which can be volatile in the surgical and medical instruments industry.
Analyst Insight
Investors should scrutinize the total compensation packages, particularly the equity components, for Eric Olson and B. Sonny Bal to assess potential dilution and alignment with long-term shareholder interests. Evaluate the performance metrics tied to these equity awards to ensure they are rigorous and promote sustainable growth for Sintx Technologies.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Eric Olson | Member | |
| B. Sonny Bal | Member | |
| Non-Principal Executive Officers and Non-Named Executive Officers | Non-Peo Neo Member |
Key Numbers
- 2025-07-31 — Filing Date (Date the DEF 14A was filed by Sintx Technologies)
- 2024-12-31 — Conformed Period of Report End Date (End of the fiscal year covered by the executive compensation details)
- 0001269026 — Central Index Key (CIK) (Unique identifier for Sintx Technologies with the SEC)
- 001-33624 — SEC File Number (Registration number for Sintx Technologies' securities)
- 19 — Public Document Count (Number of documents included in the filing)
Key Players & Entities
- Sintx Technologies, Inc. (company) — filer of DEF 14A
- Eric Olson (person) — executive officer of Sintx Technologies
- B. Sonny Bal (person) — executive officer of Sintx Technologies
- SEC (regulator) — recipient of DEF 14A filing
- Bloomberg (company) — financial news outlet
- Salt Lake City (location) — business address of Sintx Technologies
- Delaware (location) — state of incorporation for Sintx Technologies
- AMEDICA Corp (company) — former name of Sintx Technologies
FAQ
What is the primary purpose of Sintx Technologies' DEF 14A filing on July 31, 2025?
The primary purpose of Sintx Technologies' DEF 14A filing on July 31, 2025, is to disclose executive compensation details for the fiscal year ending December 31, 2024, for key executives such as Eric Olson and B. Sonny Bal, as required by the SEC.
Which executives are specifically mentioned in Sintx Technologies' 2024 compensation disclosures?
The 2024 compensation disclosures for Sintx Technologies specifically mention Eric Olson, covering the period from January 1, 2024, to July 31, 2024, and B. Sonny Bal, covering the period from August 1, 2024, to December 31, 2024.
What types of compensation components are detailed for Sintx Technologies' executives?
The DEF 14A details compensation components such as adjustments for grant date values in the Summary Compensation Table, year-end fair value of unvested awards granted in the current year, and year-over-year differences of year-end fair values for unvested awards granted in prior years for Sintx Technologies' executives.
How does Sintx Technologies' executive compensation impact shareholders?
Sintx Technologies' executive compensation, particularly the equity award components for executives like Eric Olson and B. Sonny Bal, can impact shareholders through potential dilution of existing shares if not managed effectively, making it a key factor for investor consideration.
What is the fiscal year end for Sintx Technologies, Inc.?
Sintx Technologies, Inc. has a fiscal year end of December 31, as indicated in the filing data.
Where is Sintx Technologies' business address located?
Sintx Technologies' business address is located at 1885 West 2100 Street, Salt Lake City, UT 84119.
What was Sintx Technologies' former company name?
Sintx Technologies' former company name was AMEDICA Corp, with a name change occurring on December 31, 2012.
What industry does Sintx Technologies operate in?
Sintx Technologies operates in the Surgical & Medical Instruments & Apparatus industry, classified under SIC code 3841.
Does the DEF 14A filing provide specific revenue or net income figures for Sintx Technologies?
No, the DEF 14A filing primarily focuses on executive compensation and does not provide specific revenue or net income figures for Sintx Technologies.
Why is transparency in executive compensation important for Sintx Technologies?
Transparency in executive compensation for Sintx Technologies is important because it allows investors to assess how leadership is incentivized, ensuring alignment with company performance and long-term shareholder value, especially in the competitive medical instruments sector.
Industry Context
Sintx Technologies operates in the medical technology sector, specifically focusing on advanced materials like silicon nitride for medical implants and industrial applications. The competitive landscape involves companies developing innovative biomaterials and medical devices, where intellectual property and regulatory approvals are critical. Trends include the increasing demand for durable and biocompatible implant materials and the ongoing development of new applications for advanced ceramics.
Regulatory Implications
As a medical technology company, Sintx Technologies is subject to stringent regulatory oversight from bodies like the FDA for its medical products. Compliance with manufacturing standards, clinical trial requirements, and post-market surveillance are crucial. Changes in healthcare policy or reimbursement rates could also impact market access and revenue for its products.
What Investors Should Do
- Review the detailed breakdown of executive compensation components (salary, bonus, equity awards) once specific dollar amounts are available in subsequent filings to assess alignment with company performance.
- Monitor future filings for changes in executive compensation strategy, particularly regarding equity awards, which can signal management's confidence in future growth.
- Evaluate the company's progress in commercializing its silicon nitride technology, as this is key to future revenue generation and executive compensation justification.
Key Dates
- 2025-07-31: DEF 14A Filing — Indicates the company is providing updated executive compensation information and other disclosures to shareholders.
- 2024-12-31: Fiscal Year End — The period for which the executive compensation and other financial data in the filing are reported.
- 2024-07-31: Mid-Year Reporting Period End — Marks the end of the first reporting period for Eric Olson's compensation details within the fiscal year.
- 2024-08-01: Mid-Year Reporting Period Start — Marks the start of the second reporting period for B. Sonny Bal's compensation details within the fiscal year.
- 2023-12-31: Prior Fiscal Year End — Provides a comparative period for executive compensation and other disclosures.
Glossary
- DEF 14A
- A proxy statement filed with the SEC by publicly traded companies that provides information to shareholders regarding matters to be voted on at an annual or special meeting of shareholders. This specific filing details executive compensation. (This is the primary document analyzed, providing insights into executive pay structures.)
- Summary Compensation Table
- A table within a proxy statement that summarizes the total compensation paid to the company's named executive officers for the last three fiscal years. (Although specific values are not provided in the text, it's the standard table for reporting executive pay components.)
- Grant Date Values
- The fair value of equity awards (like stock options or restricted stock) as of the date they were granted to an executive. (Used to account for the value of compensation awarded in the form of equity.)
- Year-End Fair Value of Unvested Awards
- The estimated market value of equity awards that have been granted but have not yet vested, calculated at the end of the fiscal year. (Reflects the potential future value of compensation tied to stock performance.)
- Year-Over-Year Difference
- The change in a specific metric (in this case, the fair value of unvested awards) between two consecutive fiscal years. (Helps investors understand trends in the value of outstanding equity awards.)
- Fair Values at Vest Date
- The market value of equity awards at the point when the executive becomes entitled to them (vesting). (Represents the realized value of equity compensation upon vesting.)
- Non-Principal Executive Officers and Non-Named Executive Officers
- Employees who hold executive positions but are not among the highest-paid executives whose compensation is individually disclosed in the Summary Compensation Table. (Indicates that compensation details are provided for a broader group of executives beyond the top named individuals.)
Year-Over-Year Comparison
This DEF 14A filing for the fiscal year ending December 31, 2024, continues the practice of detailing executive compensation components, including adjustments for grant date values and fair values of unvested awards, similar to the previous year's reporting structure. However, specific comparative financial metrics like revenue growth or margin changes are not present in this compensation-focused filing, making a direct quantitative comparison to the prior year's financial performance impossible based solely on this document.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 31, 2025 by Eric Olson regarding Sintx Technologies, Inc. (SINT).